For more: | FasterCures working to demystify health data with award from PCORI | Partnering for Cures is heading to innovation hotspots
April 20, 2017
FOLLOW FASTERCURES ONLINE  FacebookTwitter
FasterCures SmartBrief
Faster News for FasterCures
SIGN UP ⋅   FORWARD
Top News
WHO reports progress in fight against neglected tropical diseases
WHO reports progress in fight against neglected tropical diseases.
(Bulent Kilic/AFP/Getty Images)
A global effort led by the World Health Organization to control or eradicate neglected tropical diseases by 2020 has made progress since its founding in 2007, according to a report presented at the Global Partners' Meeting. The approach involves preventive chemotherapy, innovative disease management, vector control, veterinary public health, and provision of water and sanitation.
CNN (4/18) 
LinkedIn Twitter Facebook Google+ Email
 
News from FasterCures
FasterCures working to demystify health data with award from PCORI
FasterCures
FasterCures recognizes a knowledge gap exists between what people understand about the R&D system and what the system asks them to do. A relatively small number of participants are highly engaged with the R&D system, while their peers haven't been informed about the complex data infrastructure supporting their health care. To help bridge the gap, FasterCures is developing a tool to help people understand what makes up their health data, how they are collected and shared, and who uses them. This project is funded through the Eugene Washington PCORI Engagement Award program. Learn more.
LinkedIn Twitter Facebook Google+ Email
 
Partnering for Cures is heading to innovation hotspots
FasterCures
This year, we have been inspired by our locations to change up the way we conduct these meetings. Each meeting will be a carefully curated and highly interactive experience. In Boston, look for sessions on partnering locally for productivity and how the federal landscape affects the ecosystem. In San Francisco, we will explore how the tech industry is influencing life sciences and why medical research needs more data scientists. Register to attend today!
LinkedIn Twitter Facebook Google+ Email
 
Learn more about FasterCures:
FasterCures Home | Milken Institute
Science and Technology
RNA sequencing may reveal mutations not detected by DNA sequencing
Sequencing the RNA of skeletal muscle biopsies from patients with undiagnosed disorders revealed disease-causing genetic mutations in 17 of 50 patients, researchers reported in Science Translational Medicine. The researchers identified disease-causing mutations in the dystrophin gene in patients with Duchenne muscular dystrophy, and severe collagen VI-related myopathy intron mutation that had been missed in DNA sequencing.
The Scientist online (4/19) 
LinkedIn Twitter Facebook Google+ Email
Edible "CRISPR pill" in development to cause bacterial self-destruction
University of Wisconsin-Madison researchers are developing edible probiotic therapies, such as a pill or liquid that contains a customizable CRISPR message, to possibly treat infectious diseases caused by pathogens such as Clostridium difficile. The pill would contain bacteriophage that will deliver the CRISPR message to pathogens such as C. diff., resulting in the bacteria destroying its own DNA.
MIT Technology Review online (free registration) (4/17),  Futurism (4/17) 
LinkedIn Twitter Facebook Google+ Email
Chemist proposes collaborative biosynthesis initiative
Chemist Martin Burke proposed at the recent American Chemical Society meeting that his colleagues embark on a mission to synthesize most of the world's known organic natural products made by microbes, plants and animals -- an undertaking Burke estimates could take 20 years and cost $1 billion. Identifying, isolating and testing natural products is slow and complicated, but Burke and his colleagues developed a machine that simplifies the process.
ScienceMag.org (4/19) 
LinkedIn Twitter Facebook Google+ Email
Study validates use of CRISPR to correct DMD-linked mutation
Researchers report in Science Advances that they corrected gene mutations that cause Duchenne muscular dystrophy using CRISPR-Cpf1 in mice and patient-derived stem cells. Function was at least partially restored in cardiomyocyte cultures, and the results show the potential of CRISPR-Cpf1 to correct disease-causing genetic mutations, experts said.
The Scientist (free registration) (4/2017) 
LinkedIn Twitter Facebook Google+ Email
Finance and Economics
Scientists propose self-organized research fund allocation
Two researchers are proposing that scientists receive equal shares of national research funds, then allocate half of the grant money they receive to colleagues they cite in their papers. The system "is not based on committees' judgments, but on the wisdom of the crowd," said ecologist Marten Scheffer, who is advocating for the system along with computer scientist Johan Bollen, who pioneered the idea of self-organized fund allocation.
ScienceMag.org (4/13) 
LinkedIn Twitter Facebook Google+ Email
Gates urges continued focus on neglected tropical diseases
The Bill & Melinda Gates Foundation, drugmakers and leaders of Western countries vowed continued support for the global effort to eradicate most neglected tropical diseases. With a "broader, deeper bench of investors," the goal of treating 90% of those who need it by 2030 is attainable, Bill Gates said.
Reuters (4/19) 
LinkedIn Twitter Facebook Google+ Email
Ohio sets aside $20M for studies addressing opioid addiction
Ohio will put $20 million toward research to fight opioid addiction, Republican Gov. John Kasich said in his State of the State speech. The money will come from Ohio's Third Frontier program and will go toward research to develop new ways to ease opioid withdrawal and relieve pain.
The National Law Review (4/19) 
LinkedIn Twitter Facebook Google+ Email
Policy and Regulation
Economists propose FDA hedges to spread R&D risk
A group of economists proposed developing a system under which drug developers could purchase "exchange-traded FDA binary options" that would pay a specified sum if an experimental treatment fails to pass the FDA approval process. The options would "allow medical R&D investors to better share the pipeline risk associated with FDA approval with broader capital markets," the economists wrote.
Regulatory Focus (4/19) 
LinkedIn Twitter Facebook Google+ Email
Society and Ethics
Tech giants shake up biomedical R&D
Life science innovations increasingly come not from established drugmakers but from Apple, Google spinoff Alphabet and other big technology companies, writes John Nosta. The trend might be a wake-up call for Big Pharma, Nosta writes.
Forbes (4/15) 
LinkedIn Twitter Facebook Google+ Email
FasterCures is an action tank that works across sectors and diseases to improve the effectiveness and efficiency of the medical research enterprise. FasterCures, a center of the Milken Institute, is nonpartisan and independent of interest groups.
Contact Us
FasterCures
1101 New York Avenue, NW
Suite 620
Washington, DC 20005
(202) 336-8900 | www.fastercures.org
 
Media Inquiries
Karen Rogers
Director, Strategic Outreach
202.336.8919
krogers@fastercures.org
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Editor  -  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information